Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data

1. Coles, A.J.
2. Jones, J.L.
3. Vermersch, P.
4. Traboulsee, A.
5. Bass, A.D.
6. Boster, A.
7. Chan, A.
8. Comi, G.
9. Fernández, Ó.
10. Giovannoni, G.
11. Kubala Havrdova, E.
12. LaGanke, C.
13. Montalban, X.
14. Oreja-Guevara, C.
15. Piehl, F.
16. Wiendl, H.
17. Ziemssen, T.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1177/13524585211061335 GOOGLE SCHOLAR lock_openOpen access editor

Data source: Scopus